Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells

Cancer Research

Volumn 66, Issue 6, 2006, Pages 2937-2945

  Yin, Jun ^a,b   Hashimoto, Ayako ^a,c   Izawa, Mineko ^a   Miyazaki, Keiko ^a,c   Chen, Guo Yun ^a,c   Takematsu, Hiromu ^d   Kozutsumi, Yasunori ^d   Suzuki, Akemi ^d   Furuhata, Kimio ^e   Cheng, Feng Leng ^f   Lin, Chun Hung ^f   Sato, Chihiro ^b   Kitajima, Ken ^b   Kannagi, Reiji ^a,c  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d Japan Science and Technology Agency   (Japan)

^e KITASATO UNIVERSITY   (Japan)

^f INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CARRIER PROTEIN; CYTIDINE PHOSPHATE N ACETYL SIALIC ACID HYDROXYLASE; GANGLIOSIDE; GLUCOSE; MESSENGER RNA; N GLYCOLYLSIALIC ACID; SIALIC ACID; SIALIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL HYPOXIA; COLON CANCER; CONTROLLED STUDY; CULTURE MEDIUM; GENETIC TRANSFECTION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CACO-2 CELLS; CELL HYPOXIA; CELL LINE, TUMOR; COLON; COLONIC NEOPLASMS; CULTURE MEDIA; EPITHELIAL CELLS; G(M2) GANGLIOSIDE; HUMANS; IMMUNOHISTOCHEMISTRY; MIXED FUNCTION OXYGENASES; N-ACETYLNEURAMINIC ACID; ORGANIC ANION TRANSPORTERS; SYMPORTERS; TRANSFECTION;

EID: 33645532616     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2615     Document Type: Article

References (50)

1. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000;35:71-103.
2. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
3. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9 Suppl 5:10-7.
4. Koike T, Kimura N, Miyazaki K, et al. Hypoxia induces adhesion molecules on cancer cells-a missing link between Warburg effect and induction of selectin ligand carbohydrates. Proc Natl Acad Sci USA 2004;101:8132-7.
5. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004;95:377-84.
6. Kannagi R. Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression-the Warburg effect revisited. Glycoconj J 2004;20:353-64.
7. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 2002;99:10231-3.
8. Hakomori S, Kannagi R. Glycosphingolipids as tumor-associated and differentiation markers: a guest editorial. J Natl Cancer Inst 1983;71:231-51.
9. Zhang S, Cordon-Cardo C, Zhang HS, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer 1997;73:42-9.
10. Tsuchida T, Saxton RE, Irie RF. Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 1987;78:55-60.
11. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 2005;174:5706-12.
12. Chapman PB, Morrissey DM, Panageas KS, et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res 2000;6:874-9.
13. Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995;55:2783-8.
14. Kitamura K, Livingston PO, Fortunato SR, et al. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci U S A 1995;92:2805-9.
15. Lloyd KO. Carbohydrate vaccines for the immunotherapy of cancer. Drug News Perspect 2000;13:463-70.
16. Livingston P. Ganglioside vaccines with emphasis on GM2. Semin Oncol 1998;25:636-45.
17. Parajuli P, Yanagawa H, Hanibuchi M, et al. Humanized anti-ganglioside GM2 antibody is effective to induce antibody-dependent cell-mediated cytotoxicity in mononuclear cells from lung cancer patients. Cancer Lett 2001;165:179-84.
18. Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Miki T, Sone S. Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966. Clin Exp Metastasis 2000;18:353-60.
19. Nakamura K, Koike M, Shitara K, et al. Chimeric anti-ganglioside GM2 antibody with antitumor activity. Cancer Res 1994;54:1511-6.
20. Fukumoto H, Nishio K, Ohta S, et al. Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo. Int J Cancer 1999;82:759-64.
21. Livingston P, Zhang S, Adluri S, et al. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol Immunother 1997;43:324-30.
22. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
23. Marquina G, Waki H, Fernandez LE, et al. Gangliosides expressed in human breast cancer. Cancer Res 1996;56:5165-71.
24. Kawai T, Kato A, Higashi H, Kato S, Naiki M. Quantitative determination of N-glycolylneuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor-associated sialic acid by gas chromatography-mass spectrometry. Cancer Res 1991;51:1242-6.
25. Higashi H, Hirabayashi Y, Fukui Y, et al. Characterization of N-glycolylneuraminic acid-containing gangliosides as tumor-associated Hanganutziu-Deicher antigen in human colon cancer. Cancer Res 1985;45:3796-802.
26. Nishimaki T, Kano K, Milgrom F. Hanganutziu-Deicher antigen and antibody in pathologic sera and tissues. J Immunol 1979;122:2314-8.
27. Kawano T, Koyama S, Takematsu H, et al. Molecular cloning of cytidine monophospho-N-acetylneuraminic acid hydroxylase. Regulation of species- and tissue-specific expression of N-glycolylneuraminic acid. J Biol Chem 1995;270:16458-63.
28. Schlenzka W, Shaw L, Kelm S, et al. CMP-N-acetylneuraminic acid hydroxylase: the first cytosolic Rieske iron-sulphur protein to be described in Eukarya. FEBS Lett 1996;385:197-200.
29. Irie A, Suzuki A. CMP-N-acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem Biophys Res Commun 1998;248:330-3.
30. Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem 1998;273:15866-71.
31. Chou HH, Hayakawa T, Diaz S, et al. Inactivation of CMP-N- acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution. Proc Natl Acad Sci U S A 2002;99:11736-41.
32. Malykh YN, Schauer R, Shaw L. N-Glycolylneuraminic acid in human tumours. Biochimie 2001;83:623-34.
33. Carr A, Rodriguez E, Arango Mdel C, et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol 2003;21:1015-21.
34. Nakarai H, Chandler PJ, Kano K, Morton DL, Irie RF. Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma. Int Arch Allergy Immunol 1990;91:323-8.
35. Tanaka M, Kai T, Sun X-L, Takayanagi H, Furuhata K. Synthesis of N-glycolyl-8-O-sulfoneuraminic acid. Chem Pharm Bull (Tokyo) 1995;43:2095-8.
36. M2 gangliosides and distribution of the antigens in human lung cancer. Cancer Res 1988;48:6154-60.
37. M2 in human germ cell tumors: a study with specific monoclonal antibodies. Cancer 1990;65:499-505.
38. Hara S, Takemori Y, Yamaguchi M, Nakamura M, Ohkura Y. Fluorometric high-performance liquid chromatography of N-acetyl- and N-glycolylneuraminic acids and its application to their microdetermination in human and animal sera, glycoproteins, and glycolipids. Anal Biochem 1987;164:138-45.
39. Sato C, Inoue S, Matsuda T, Kitajima K. Development of a highly sensitive chemical method for detecting α2→8-linked oligo/polysialic acid residues in glycoproteins blotted on the membrane. Anal Biochem 1998;261: 191-7.
40. Furukawa K, Yamaguchi H, Oettgen HF, Old LJ, Lloyd KO. Analysis of the expression of N-glycolylneuraminic acid-containing gangliosides in cells and tissues using two human monoclonal antibodies. J Biol Chem 1988; 263:18507-12.
41. Higashi H, Sasabe T, Fukui Y, Maru M, Kato S. Detection of gangliosides as N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn J Cancer Res 1988;79:952-6.
42. Bardor M, Nguyen DH, Diaz S, Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 2005;280:4228-37.
43. Mancini GM, de Jonge HR, Galjaard H, Verheijen FW. Characterization of a proton-driven carrier for sialic acid in the lysosomal membrane. Evidence for a group-specific transport system for acidic monosaccharides. J Biol Chem 1989;264:15247-54.
44. Havelaar AC, Mancini GM, Beerens CE, Souren RM, Verheijen FW. Purification of the lysosomal sialic acid transporter. Functional characteristics of a monocarboxylate transporter. J Biol Chem 1998;273:34568-74.
45. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49.
46. Higashi H, Hirabayashi Y, Hirota M, Matsumoto M, Kato S. Detection of ganglioside GM2 in sera and tumor tissues of hepatoma patients. Jpn J Cancer Res 1987;78: 1309-13.
47. Tanno M, Yamada H, Kyomasu Y, Inaniwa Y, Hano H, Myoga A. Immunohistochemical localization of ganglioside components in hepatocellular carcinoma and liver cirrhosis using monoclonal antibody. Lab Invest 1993;68:456-64.
48. Nohara K, Wang F, Spiegel S. Glycosphingolipid composition of MDA-MB-231 and MCF-7 human breast cancer cell lines. Breast Cancer Res Treat 1998;48:149-57.
49. Yuyama Y, Dohi T, Monta H, Furukawa K, Oshima M. Enhanced expression of GM2/GD2 synthase mRNA in human gastrointestinal cancer. Cancer 1995;75: 1273-80.
50. Furukawa K, Akagi T, Nagata Y, et al. GD2 ganglioside on human T-lymphotropic virus type I-infected T cells: possible activation of β,1,4-N-acetylgalactosaminyl-transferase gene by p40tax. Proc Natl Acad Sci U S A 1993;90:1972-6.